drugset
drugset / Trial / NCT07637162

Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

NCT07637162 ↗

Phase 3 Enrolling by invitation 300 enrolled Axsome Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia.

Timeline

Start
2026-04-29
Primary completion
2028-05
Completion
2028-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AXS-14 Unknown — —

Indications

fibromyalgia